Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
Q4 2023 vs. Q3 2023
How the institutions holding Ambrx Biopharma, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 44 | 1 | 68 | +25 |
| Shares | 49.4M | 31.1K | 64.1M | +14.7M (+29.8%) |
| Value | $568.3M | $358.1K | $912.7M | +$344.7M (+60.7%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (34)
Institutions that held Ambrx Biopharma, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (9)
Institutions that held Ambrx Biopharma, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Commodore Capital LP | 3,518,556 | $40.5M |
| Holocene Advisors, LP | 486,562 | $5.60M |
| First Manhattan Co | 135,003 | $1.55M |
| Bank of New York Mellon Corp | 47,433 | $545.5K |
| Alps Advisors Inc | 45,531 | $523.6K |
| Apis Capital Advisors, LLC | 34,000 | $391.0K |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 31,735 | $365.0K |
| Group One Trading, L.P. | 2,155 | $24.8K |
| Legal & General Group Plc | 1,381 | $15.9K |
Not filed for Q4 2023 yet (1)
Institutions that held Ambrx Biopharma, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Innovis Asset Management LLC | 31,137 | $358.1K |